Standout Papers
- The Diagnosis of Mild Cognitive Impairment due to Alzheimer’s Disease: Recommendations from the National Institute on Aging-Alzheimer’s Association Workgroups on Diagnostic Guidelines for Alzheimer’s Disease (2013)
- Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria (2007)
- The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease (2011)
- Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis (2006)
Citation Impact
Citing Papers
How cognitive and reactive fear circuits optimize escape decisions in humans
2018 StandoutNobel
National Institute of Neurological Disorders and Stroke–Canadian Stroke Network Vascular Cognitive Impairment Harmonization Standards
2006 Standout
TDP-43 repression of nonconserved cryptic exons is compromised in ALS-FTD
2015 Science
TDP-43 Mutations in Familial and Sporadic Amyotrophic Lateral Sclerosis
2008 StandoutScience
Expanded GGGGCC repeat RNA associated with amyotrophic lateral sclerosis and frontotemporal dementia causes neurodegeneration
2013
MicroRNA-206 Delays ALS Progression and Promotes Regeneration of Neuromuscular Synapses in Mice
2009 Science
A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease
2011
Sporadic and hereditary amyotrophic lateral sclerosis (ALS)
2014
Loss of C9 ORF 72 impairs autophagy and synergizes with polyQ Ataxin‐2 to induce motor neuron dysfunction and cell death
2016
Donepezil for dementia due to Alzheimer's disease
2018
Introduction to the recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
2011
Apathy associated with neurocognitive disorders: Recent progress and future directions
2016
The TDP‐43 N‐terminal domain structure at high resolution
2016
Antisense RNA foci in the motor neurons of C9ORF72-ALS patients are associated with TDP-43 proteinopathy
2015
Posterior cerebral atrophy in the absence of medial temporal lobe atrophy in pathologically-confirmed Alzheimer's disease
2011
Roles of tau protein in health and disease
2017
TAR DNA-binding protein 43 (TDP-43) liquid–liquid phase separation is mediated by just a few aromatic residues
2018
The physiological and pathological biophysics of phase separation and gelation of RNA binding proteins in amyotrophic lateral sclerosis and fronto-temporal lobar degeneration
2018
Functional and dynamic polymerization of the ALS-linked protein TDP-43 antagonizes its pathologic aggregation
2017
Aggregation of the nucleic acid–binding protein TDP-43 occurs via distinct routes that are coordinated with stress granule formation
2019
A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease
2017
Altered Ribostasis: RNA-Protein Granules in Degenerative Disorders
2013
Templated Aggregation of TAR DNA-binding Protein of 43 kDa (TDP-43) by Seeding with TDP-43 Peptide Fibrils
2016
The role of liquid–liquid phase separation in aggregation of the TDP-43 low-complexity domain
2019 Standout
Ionotropic Glutamate Receptors & CNS Disorders
2008
Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy
2009
Focal cortical presentations of Alzheimer's disease
2007
“Structural characterization of the minimal segment of TDP-43 competent for aggregation”
2014
Diagnostic Criteria for Vascular Cognitive Disorders
2014
ALS-Linked Mutations Enlarge TDP-43-Enriched Neuronal RNA Granules in the Dendritic Arbor
2014
Two mutations G335D and Q343R within the amyloidogenic core region of TDP-43 influence its aggregation and inclusion formation
2016
Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics
2007
Multiple roles of TDP-43 in gene expression, splicing regulation, and human disease
2007
Memantine in Moderate-to-Severe Alzheimer's Disease
2003 Standout
Combining MRI and CSF measures for classification of Alzheimer's disease and prediction of mild cognitive impairment conversion
2012
CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment
2009
Dipeptide repeat protein pathology in C9ORF72 mutation cases: clinico-pathological correlations
2013
Tar DNA Binding Protein-43 (TDP-43) Associates with Stress Granules: Analysis of Cultured Cells and Pathological Brain Tissue
2010
Diagnosis-Independent Alzheimer Disease Biomarker Signature in Cognitively Normal Elderly People
2010
Plasma phospholipids identify antecedent memory impairment in older adults
2014
Untargeted Metabolomic Analysis of Human Plasma Indicates Differentially Affected Polyamine and L-Arginine Metabolism in Mild Cognitive Impairment Subjects Converting to Alzheimer’s Disease
2015
TDP-43 is deposited in the Guam parkinsonism-dementia complex brains
2007
Vascular dementia
2015 Standout
Is there pure vascular dementia in old age?
2010
Channel opening and gating mechanism in AMPA-subtype glutamate receptors
2017 StandoutNatureNobel
High performance plasma amyloid-β biomarkers for Alzheimer’s disease
2018 NatureNobel
Mechanisms Underlying Inflammation in Neurodegeneration
2010 Standout
The cleavage pattern of TDP-43 determines its rate of clearance and cytotoxicity
2015
Oxidative Stress Hypothesis in Alzheimer's Disease
1997 Standout
Associations of genetic polymorphisms of Siglecs with human diseases
2014
Brain distribution of dipeptide repeat proteins in frontotemporal lobar degeneration and motor neurone disease associated with expansions in C9ORF72
2014
CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease
2006
TDP43-Positive Intraneuronal Inclusions in a Patient with Motor Neuron Disease and Parkinson’s Disease
2010
Systematic Review of the Diagnostic Accuracy of 99mTc-HMPAO-SPECT in Dementia
2004
Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide
2007 Standout
Enrichment of C-Terminal Fragments in TAR DNA-Binding Protein-43 Cytoplasmic Inclusions in Brain but not in Spinal Cord of Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis
2008
TDP-43 and FUS/TLS: emerging roles in RNA processing and neurodegeneration
2010
Stop Alzheimer’s before it starts
2017 Nature
The clinical use of structural MRI in Alzheimer disease
2010
ALS-Causing Mutations Significantly Perturb the Self-Assembly and Interaction with Nucleic Acid of the Intrinsically Disordered Prion-Like Domain of TDP-43
2016
Alzheimer's disease
2011 Standout
Amyloid imaging in mild cognitive impairment subtypes
2009
Programmable RNA Tracking in Live Cells with CRISPR/Cas9
2016 StandoutNobel
Mild Cognitive Impairment
2011 Standout
The C-Terminal TDP-43 Fragments Have a High Aggregation Propensity and Harm Neurons by a Dominant-Negative Mechanism
2010
TDP-43 Proteinopathy in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis
2007
Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study
2010
Severe Alzheimer’s Disease: Treatment Effects on Function and Care Requirements
2010
Spreading of pathology in neurodegenerative diseases: a focus on human studies
2015
Hexanucleotide Repeats in ALS/FTD Form Length-Dependent RNA Foci, Sequester RNA Binding Proteins, and Are Neurotoxic
2013
Functional network disruption in the degenerative dementias
2011
Neuroimaging in Alzheimer disease: an evidence-based review
2003
Atomic structures of TDP-43 LCD segments and insights into reversible or pathogenic aggregation
2018
Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial
2008
The Evolution of Preclinical Alzheimer’s Disease: Implications for Prevention Trials
2014
Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease
2010
Residue-by-Residue View of In Vitro FUS Granules that Bind the C-Terminal Domain of RNA Polymerase II
2015
Exosomes as new diagnostic tools in CNS diseases
2015
Amyotrophic lateral sclerosis
2011 Standout
rCBF and cognitive impairment changes assessed by SPECT and ADAS-cog in late-onset Alzheimer’s disease after 18 months of treatment with the cholinesterase inhibitors donepezil or galantamine
2017
TRIBE: Hijacking an RNA-Editing Enzyme to Identify Cell-Specific Targets of RNA-Binding Proteins
2016 StandoutNobel
TAR-DNA Binding Protein 43 in Pick Disease
2008
Mechanisms of FUS mutations in familial amyotrophic lateral sclerosis
2016
TDP‐43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease
2007
Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period
2005
C9orf72 Dipeptide Repeats Impair the Assembly, Dynamics, and Function of Membrane-Less Organelles
2016
Modeling the Association between 43 Different Clinical and Pathological Variables and the Severity of Cognitive Impairment in a Large Autopsy Cohort of Elderly Persons
2008
Mutations in SQSTM1 encoding p62 in amyotrophic lateral sclerosis: genetics and neuropathology
2013
Progranulin Mediates Caspase-Dependent Cleavage of TAR DNA Binding Protein-43
2007
EFNS guidelines for the diagnosis and management of Alzheimer’s disease
2010
TDP-43 NTD can be induced while CTD is significantly enhanced by ssDNA to undergo liquid-liquid phase separation
2018
CSF Biomarkers
2009
Risk score for prediction of 10 year dementia risk in individuals with type 2 diabetes: a cohort study
2013
Cognitive impairment in amyotrophic lateral sclerosis
2007
ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trials
2016
Autophagy: Renovation of Cells and Tissues
2011 Standout
Novel Ubiquitin Neuropathology in Frontotemporal Dementia WithValosin-Containing ProteinGene Mutations
2006
Structural Transformation of the Amyloidogenic Core Region of TDP-43 Protein Initiates Its Aggregation and Cytoplasmic Inclusion
2013
Systemic dysregulation of TDP-43 binding microRNAs in amyotrophic lateral sclerosis
2013
A Novel CpG-free Vertebrate Insulator Silences the Testis-specific SP-10 Gene in Somatic Tissues
2007
Chapter 1 The Molecular Links Between TDP‐43 Dysfunction and Neurodegeneration
2009
Decoding ALS: from genes to mechanism
2016 StandoutNature
Discriminant analysis of longitudinal cortical thickness changes in Alzheimer's disease using dynamic and network features
2011
Biomarkers in amyotrophic lateral sclerosis
2008
TDP-43 is a key player in the clinical features associated with Alzheimer’s disease
2014
ALS Mutations Disrupt Phase Separation Mediated by α-Helical Structure in the TDP-43 Low-Complexity C-Terminal Domain
2016
Treatment for Rheumatoid Arthritis and Risk of Alzheimer’s Disease: A Nested Case-Control Analysis
2016
Eukaryotic Stress Granules Are Cleared by Autophagy and Cdc48/VCP Function
2013
A multinational, randomised, 12‐week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease
2004
Alzheimer Disease: An Update on Pathobiology and Treatment Strategies
2019 Standout
Hierarchical feature representation and multimodal fusion with deep learning for AD/MCI diagnosis
2014 Standout
Long term incidence of dementia, predictors of mortality and pathological diagnosis in older stroke survivors
2011
Statins for the prevention of dementia
2009
Protein kinase and protein phosphatase expression in amyotrophic lateral sclerosis spinal cord
2003
Regulatory Innovation and Drug Development for Early-Stage Alzheimer's Disease
2013
The amyloidogenicity of a C-terminal region of TDP-43 implicated in Amyotrophic Lateral Sclerosis can be affected by anions, acetylation and homodimerization
2018
Oxidative stress and Alzheimer disease
2000 Standout
An ALS-mutant TDP-43 neurotoxic peptide adopts an anti-parallel β-structure and induces TDP-43 redistribution
2014
Alzheimer's disease
2015
Safety, tolerability and immunogenicity of an active anti-Aβ40 vaccine (ABvac40) in patients with Alzheimer’s disease: a randomised, double-blind, placebo-controlled, phase I trial
2018
Safety and tolerability of BAN2401 - a clinical study in Alzheimer’s disease with a protofibril selective Aβ antibody
2016
AddNeuroMed—The European Collaboration for the Discovery of Novel Biomarkers for Alzheimer's Disease
2009
Delineation of the Core Aggregation Sequences of TDP‐43 C‐Terminal Fragment
2011
Vascular cognitive impairment
2003 Standout
Behavioral and Psychological Symptoms of Dementia
2012
Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study
2013 Standout
Neuronal inclusion protein TDP-43 has no primary genetic role in FTD and ALS
2008
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
2009 Standout
Donepezil in Alzheimer’s Disease: What to Expect after 3 Years of Treatment in a Routine Clinical Setting
2006
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease
2010
Gene expression analysis of frontotemporal lobar degeneration of the motor neuron disease type with ubiquitinated inclusions
2007
Pharmaceutical and medicinal significance of sulfur (SVI)-Containing motifs for drug discovery: A critical review
2018 Standout
Unconventional Translation of C9ORF72 GGGGCC Expansion Generates Insoluble Polypeptides Specific to c9FTD/ALS
2013
Meta-analysis based SVM classification enables accurate detection of Alzheimer's disease across different clinical centers using FDG-PET and MRI
2012
Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives
2010
Brain Amyloid Imaging
2011
Neural-specific Deletion of FIP200 Leads to Cerebellar Degeneration Caused by Increased Neuronal Death and Axon Degeneration
2009
Current and evolving treatment strategies for the Alzheimer disease continuum
2020
TDP-43 Proteinopathy and Motor Neuron Disease in Chronic Traumatic Encephalopathy
2010
Rivastigmine for Alzheimer's disease
2000
Diabetes mellitus and the Risk of Dementia, Alzheimer’s Disease and Vascular Cognitive Impairment in the Canadian Study of Health and Aging
2002
TDP-43 Is Intrinsically Aggregation-prone, and Amyotrophic Lateral Sclerosis-linked Mutations Accelerate Aggregation and Increase Toxicity
2009
Transactive Response DNA-Binding Protein 43 Burden in Familial Alzheimer Disease and Down Syndrome
2009
Alzheimer's disease
2016 Standout
Amyotrophic lateral sclerosis—a model of corticofugal axonal spread
2013
Delineating the membrane-disrupting and seeding properties of the TDP-43 amyloidogenic core
2013
Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study
2007
TDP-43 high throughput screening analyses in neurodegeneration: Advantages and pitfalls
2013
Aβ amyloid and glucose metabolism in three variants of primary progressive aphasia
2008
Cellular and Molecular Mechanisms of Pain
2009 StandoutNobel
The epidemiology of ALS: a conspiracy of genes, environment and time
2013
Biomarker Modeling of Alzheimer’s Disease
2013
“New Old Pathologies”: AD, PART, and Cerebral Age-Related TDP-43 With Sclerosis (CARTS)
2016
TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis
2006 Standout
Mild Cognitive Impairment
2009
Alzheimer's Disease
2010 Standout
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
2014
The physical forces mediating self-association and phase-separation in the C-terminal domain of TDP-43
2017
Progression of Mild Cognitive Impairment to Dementia in Clinic- vs Community-Based Cohorts
2009
TDP-43 gene analysis in frontotemporal lobar degeneration
2007
Phosphorylation of S409/410 of TDP-43 is a consistent feature in all sporadic and familial forms of TDP-43 proteinopathies
2009
Increased brain atrophy rates in cognitively normal older adults with low cerebrospinal fluid Aβ1‐42
2010
Long-term Course and Effectiveness of Combination Therapy in Alzheimer Disease
2008
Use of drug treatments for Alzheimer's disease in France: a study on a national level based on the National Alzheimer's Data Bank (Banque Nationale Alzheimer)
2012
Automatic classification of patients with Alzheimer's disease from structural MRI: A comparison of ten methods using the ADNI database
2010
MicroRNAs as Potential Circulating Biomarkers for Amyotrophic Lateral Sclerosis
2014
Risk of dementia in diabetes mellitus: a systematic review
2005 Standout
Genetics of Alzheimer’s Disease
2014
Can pharmacological treatment of behavioural disturbances in elderly patients with dementia lower the burden of their family caregiver?
2009
Axonal Transport of TDP-43 mRNA Granules Is Impaired by ALS-Causing Mutations
2014
Effects of monoclonal antibodies against amyloid-β on clinical and biomarker outcomes and adverse event risks: A systematic review and meta-analysis of phase III RCTs in Alzheimer’s disease
2021
Identification of Conversion from Mild Cognitive Impairment to Alzheimer's Disease Using Multivariate Predictors
2011
A shortcut to the lysosome: The mannose-6-phosphate-independent pathway
2012
Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials
2007
Clinical amyloid imaging in Alzheimer's disease
2011
HDDD2 is a familial frontotemporal lobar degeneration with ubiquitin‐positive, tau‐negative inclusions caused by a missense mutation in the signal peptide of progranulin
2006
Updated TDP-43 in Alzheimer’s disease staging scheme
2016
Update on the Pharmacological Treatment of Alzheimers Disease
2010
Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study
2009
p62 positive, TDP-43 negative, neuronal cytoplasmic and intranuclear inclusions in the cerebellum and hippocampus define the pathology of C9orf72-linked FTLD and MND/ALS
2011
The use of PET in Alzheimer disease
2010
Lysosome-targeting chimaeras for degradation of extracellular proteins
2020 StandoutNatureNobel
Truncation and pathogenic mutations facilitate the formation of intracellular aggregates of TDP-43
2009
The road to restoring neural circuits for the treatment of Alzheimer's disease
2016 Nature
Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline
2007
Dipeptide repeat protein inclusions are rare in the spinal cord and almost absent from motor neurons in C9ORF72 mutant amyotrophic lateral sclerosis and are unlikely to cause their degeneration
2015
Characterizing the RNA targets and position-dependent splicing regulation by TDP-43
2011
Special Care Units and Traditional Care in Dementia: Relationship with Behavior, Cognition, Functional Status and Quality of Life - A Review
2013 Standout
NeuralKCNQ(Kv7) channels
2009
Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease
2009
Poly(ADP-Ribose) Prevents Pathological Phase Separation of TDP-43 by Promoting Liquid Demixing and Stress Granule Localization
2018
Challenges of multimorbidity of the aging brain: a critical update
2014
Single-cell transcriptomic analysis of Alzheimer’s disease
2019 StandoutNature
Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43
2011
TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis
2008
Quantitative analysis and clinico-pathological correlations of different dipeptide repeat protein pathologies in C9ORF72 mutation carriers
2015
Glia cells in amyotrophic lateral sclerosis: New clues to understanding an old disease?
2007
Pathways towards and away from Alzheimer's disease
2004 StandoutNature
Exosome secretion is a key pathway for clearance of pathological TDP-43
2016
The FTD/ALS-associated RNA-binding protein TDP-43 regulates the robustness of neuronal specification through microRNA-9a in Drosophila
2012
Donepezil for dementia due to Alzheimer's disease
2003
Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study
2013
Small RNAs are modified with N-glycans and displayed on the surface of living cells
2021 StandoutNobel
TDP-43 skeins show properties of amyloid in a subset of ALS cases
2012
No association of TDP-43 with sporadic frontotemporal dementia
2007
Amyloid Precursor Protein Regulates Brain Apolipoprotein E and Cholesterol Metabolism through Lipoprotein Receptor LRP1
2007
Sarcoplasmic redistribution of nuclear TDP‐43 in inclusion body myositis
2009
A Long-Term Comparison of Galantamine and Donepezil in the Treatment of Alzheimer???s Disease
2003
Management of agitation and aggression associated with Alzheimer disease
2009
Clinical Prediction of Alzheimer Disease Dementia Across the Spectrum of Mild Cognitive Impairment
2007
Modeling neurodevelopmental disorder-associated humanAGO1mutations inCaenorhabditis elegansArgonautealg-1
2024 StandoutNobel
Soluble amyloid precursor protein (APP) regulates transthyretin and Klotho gene expression without rescuing the essential function of APP
2010 StandoutNobel
Phase to Phase with TDP-43
2017
A voxel-based morphometry study of patterns of brain atrophy in ALS and ALS/FTLD
2005
Clinical trial of an inhibitor of RAGE-Aβ interactions in Alzheimer disease
2014
Pharmacotherapeutic strategies in the treatment of severe Alzheimer’s disease
2016
Systematic Review of the Diagnostic Accuracy of 99mTc-HMPAO-SPECT in Dementia
2004
Australian population trends and disparities in cholinesterase inhibitor use, 2003 to 2010
2013
Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: the VantagE study
2008
RNA–protein analysis using a conditional CRISPR nuclease
2013 StandoutNobel
Imaging β-amyloid burden in aging and dementia
2007
Stress granules as crucibles of ALS pathogenesis
2013
Lecanemab in Early Alzheimer’s Disease
2022 Standout
Persistent neuropathological effects 14 years following amyloid-β immunization in Alzheimer’s disease
2019
Vascular alterations in PDAPP mice after anti‐Aβ immunotherapy: Implications for amyloid‐related imaging abnormalities
2013
Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis.
2008
ALS motor phenotype heterogeneity, focality, and spread
2009
Cholinesterase Inhibitors May Not Benefit Mild Cognitive Impairment and Mild Alzheimer Disease Dementia
2019
Effect of cholinergic treatment depends on cholinergic integrity in early Alzheimer’s disease
2017
Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease
2014
Cholinesterase inhibitors for mild cognitive impairment
2012
Gray Matter Atrophy in Patients With Ischemic Stroke With Cognitive Impairment
2008
Review: Prion‐like mechanisms of transactive response DNA binding protein of 43 kDa (TDP ‐43) in amyotrophic lateral sclerosis (ALS )
2014
Practice parameter: Management of dementia (an evidence-based review) [RETIRED]
2001 Standout
Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease
2013
TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration
2009
Iron accumulation in Alzheimer disease is a source of redox-generated free radicals
1997
Memantine for dementia
2006
A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer’s disease dementia
2019
Practice parameter: Diagnosis of dementia (an evidence-based review)
2001
Correcting for the Absence of a Gold Standard Improves Diagnostic Accuracy of Biomarkers in Alzheimer’s Disease
2015
Diagnostic impact of CSF biomarkers for Alzheimer's disease in a tertiary memory clinic
2014
2012 Alzheimer's disease facts and figures Alzheimer's Association ∗
2012 Standout
A single N‐terminal phosphomimic disrupts TDP‐43 polymerization, phase separation, and RNA splicing
2018
Donepezil HCl (E2020) Maintains Functional Brain Activity in Patients With Alzheimer Disease: Results of a 24-Week, Double-Blind, Placebo-Controlled Study
2003
Spermidine in health and disease
2018 StandoutScience
Donepezil treatment of patients with MCI
2009
How neuroinflammation contributes to neurodegeneration
2016 StandoutScience
A Clinical Overview of Cholinesterase Inhibitors in Alzheimer’s Disease
2002
Mild cognitive impairment: Disparity of incidence and prevalence estimates
2012
A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease
2011
The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
2011 Standout
An inflammatory and trophic disconnect biomarker profile revealed in Down syndrome plasma: Relation to cognitive decline and longitudinal evaluation
2016
The biology , function , and biomedical applications of exosomes
2020 StandoutScience
Validation of an optimized SPM procedure for FDG-PET in dementia diagnosis in a clinical setting
2014
The role of extracellular vesicles in neurodegenerative diseases
2016
Autophagy activators rescue and alleviate pathogenesis of a mouse model with proteinopathies of the TAR DNA-binding protein 43
2012
The Alzheimer's Prevention Initiative Generation Program: Study design of two randomized controlled trials for individuals at risk for clinical onset of Alzheimer's disease
2019
Targeting RNA Foci in iPSC-Derived Motor Neurons from ALS Patients with a C9ORF72 Repeat Expansion
2013
Position Statement of the American Association for Geriatric Psychiatry Regarding Principles of Care for Patients With Dementia Resulting From Alzheimer Disease
2006
Religious Orders Study and Rush Memory and Aging Project
2018 Standout
Glucose metabolism, gray matter structure, and memory decline in subjective memory impairment
2012
The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease
2018 Standout
Donepezil for dementia due to Alzheimer's disease
2006
A Randomized, Double‐Blind, Placebo‐Controlled Study of the Efficacy and Safety of Donepezil in Patients with Alzheimer's Disease in the Nursing Home Setting
2001
Galantamine treatment of vascular dementia
2007
Early diagnosis of Alzheimer's disease using cortical thickness: impact of cognitive reserve
2009
Downregulation of MicroRNA-9 in iPSC-Derived Neurons of FTD/ALS Patients with TDP-43 Mutations
2013
2016
Emerging Targets in Photopharmacology
2016 StandoutNobel
CSF biomarkers in frontotemporal lobar degeneration with known pathology
2008
Clinical practice with anti-dementia drugs: A revised (third) consensus statement from the British Association for Psychopharmacology
2017
Microbleeds, Mortality, and Stroke in Alzheimer Disease
2015
Etanercept in Alzheimer disease
2015
Effect of Immunotherapy With Bapineuzumab on Cerebrospinal Fluid Biomarker Levels in Patients With Mild to Moderate Alzheimer Disease
2012
Efficacy and Tolerability of Donepezil in Vascular Dementia
2003
Fourth Canadian Consensus Conference on the Diagnosis and Treatment of Dementia: recommendations for family physicians.
2014
Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease
2012
Structural Neuroimaging in the Detection and Prognosis of Pre-Clinical and Early AD
2009
Alzheimer's Disease Neuroimaging Initiative (ADNI)
2009 Standout
Influence of tau PET, amyloid PET, and hippocampal volume on cognition in Alzheimer disease
2018
Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease
2014
Donanemab in Early Alzheimer’s Disease
2021
Sulfur(VI) Fluoride Exchange (SuFEx)-Enabled High-Throughput Medicinal Chemistry
2020 StandoutNobel
Using Neuroscience to Help Understand Fear and Anxiety: A Two-System Framework
2016
Rivastigmine for Alzheimer's disease
2015
Clinical practice with anti-dementia drugs: a revised (second) consensus statement from the British Association for Psychopharmacology
2010
Structural neuroimaging in the detection and prognosis of pre-clinical and early AD.
2009
Proteostasis Failure in Neurodegenerative Diseases: Focus on Oxidative Stress
2020
Valosin-containing protein (VCP) is required for autophagy and is disrupted in VCP disease
2009
Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease–Related β-Amyloid Status
2019
Traumatic injury induces stress granule formation and enhances motor dysfunctions in ALS/FTD models
2018
Caenorhabditis elegans microRNAs of the let-7 family act in innate immune response circuits and confer robust developmental timing against pathogen stress
2015 StandoutNobel
Liquid phase condensation in cell physiology and disease
2017 StandoutScience
Cholinesterase inhibitors for Alzheimer's disease
2006 Standout
Testing the Right Target and Right Drug at the Right Stage
2011
Extracellular microRNAs in human circulation are associated with miRISC complexes that are accessible to anti-AGO2 antibody and can bind target mimic oligonucleotides
2020 StandoutNobel
TDP-43 promotes microRNA biogenesis as a component of the Drosha and Dicer complexes
2012
Works of Howard Feldman being referenced
Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis
2006 StandoutScience
Definitions of dementia and predementia states in Alzheimer's disease and vascular cognitive impairment: consensus from the Canadian conference on diagnosis of dementia
2013
Regional HmPAO SPECT and CT Measurements in the Diagnosis of Alzheimer's Disease
1997
Mild Cognitive Impairment
2005
The relationship between extramotor ubiquitin-immunoreactive neuronal inclusions and dementia in motor neuron disease
2003
Outcomes of Cognitively Impaired Not Demented at 2 Years in the Canadian Cohort Study of Cognitive Impairment and Related Dementias
2006
Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial
2016
Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder
2010
Diagnosis and treatment of dementia: 2. Diagnosis
2008
The Disability Assessment for Dementia Scale: A 12-Month Study of Functional Ability in Mild to Moderate Severity Alzheimer Disease
2001
Effectiveness of Donepezil in Reducing Clinical Worsening in Patients with Mild-to-Moderate Alzheimer’s Disease
2009
Extrapyramidal features in patients with motor neuron disease and dementia; a clinicopathological correlative study
2004
A family with tau-negative frontotemporal dementia and neuronal intranuclear inclusions linked to chromosome 17
2006
Protein kinase C activity and protein levels in Alzheimer's disease
1997
A Canadian Cohort Study of Cognitive Impairment and Related Dementias (ACCORD): Study Methods and Baseline Results
2003
The “rights” of precision drug development for Alzheimer’s disease
2019
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
2007 Standout
Ubiquitin Immunohistochemistry Suggests Classic Motor Neuron Disease, Motor Neuron Disease With Dementia, and Frontotemporal Dementia of the Motor Neuron Disease Type Represent a Clinicopathologic Spectrum
2005
Serum levels of the iron binding protein p97 are elevated in Alzheimer′s disease
1996
Evaluation of late-onset Alzheimer disease genetic susceptibility risks in a Canadian population
2013
Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance
2010
A Randomized, Controlled Trial of Linopirdine in the Treatment of Alzheimer's Disease
1997
Cholesterol in Alzheimer's disease
2005
Clinical and pathological features of familial frontotemporal dementia caused by C9ORF72 mutation on chromosome 9p
2012
Efficacy of Donepezil on Behavioral Symptoms in Patients With Moderate to Severe Alzheimer’s Disease
2002
Functional, Cognitive and Behavioral Effects of Donepezil in Patients with Moderate Alzheimer's Disease
2002
Progress in Clinical Neurosciences: Canadian Guidelines for the Development of Antidementia Therapies: A Conceptual Summary
2006
The Consortium to Investigate Vascular Impairment of Cognition: Methods and First Findings
2003
Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable Workgroup
2011
Efficacy of Donepezil on Maintenance of Activities of Daily Living in Patients with Moderate to Severe Alzheimer's Disease and the Effect on Caregiver Burden
2003
Neuronal Intranuclear Inclusions Distinguish Familial FTD-MND Type from Sporadic Cases
2004
Epidemiology and genetics of frontotemporal dementia/Pick's disease
2003
Rates of Cognitive Change in Alzheimer Disease
2009
Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer's disease
2007
Neuronal intranuclear inclusions distinguish familial FTD-MND type from sporadic cases
2003
Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo‐controlled trial
2005
Dementia with Lewy bodies
2003
Treatment of Alzheimer's disease; current status and new perspectives
2003
Treatment with galantamine and time to nursing home placement in Alzheimer's disease patients with and without cerebrovascular disease
2008
The neuropathology of frontotemporal lobar degeneration caused by mutations in the progranulin gene
2006
Activities of Daily Living in Moderate-to-Severe Alzheimer Disease: An Analysis of the Treatment Effects of Memantine in Patients Receiving Stable Donepezil Treatment
2006
Sortilin-Mediated Endocytosis Determines Levels of the Frontotemporal Dementia Protein, Progranulin
2010
Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease
2010
Indomethacin for Alzheimer's disease
2002
Benefits of donepezil on performance of basic and instrumental activities of daily living in moderate to severe Alzheimer's disease
2000
P2‐200: Three cases of apparent Vasogenic Edema (VE) from a phase 2 clinical trial of the gamma secretase Inhibitor BMS‐708163 in patients with mild‐to‐moderate AD
2011
Serum p97 levels as an aid to identifying Alzheimer's disease
2001
Clinical trials and late‐stage drug development for A lzheimer's disease: an appraisal from 1984 to 2014
2014
Emerging Therapies for Vascular Dementia and Vascular Cognitive Impairment
2004
The Diagnosis of Mild Cognitive Impairment due to Alzheimer’s Disease: Recommendations from the National Institute on Aging-Alzheimer’s Association Workgroups on Diagnostic Guidelines for Alzheimer’s Disease
2013 Standout
The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): Design and baseline characteristics
2008
P1-386 Pharmacoeconomic benefits of donepezil treatment in severe Alzheimer's disease
2004
P3–176: High prevalence of multiple brain pathologies in dementia
2006
The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
2011 Standout
Safety and efficacy of galantamine in subjects with mild cognitive impairment
2008
Use of the severe impairment battery in a clinical trial of donepezil in moderate to severe Alzheimer's disease
2000
A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers
2016
Donepezil treatment in patients with moderate to severe Alzheimer's disease reduces caregiver stress
2000
Effects of donepezil on behaviour and other domains in moderate to severe Alzheimer's disease
2000
Progression of impairment in patients with vascular cognitive impairment without dementia
2001
Can we prevent Alzheimer's disease? Secondary “prevention” trials in Alzheimer's disease
2013
Behavioral symptoms in mild cognitive impairment
2004
The staging and assessment of moderate to severe Alzheimer disease
2005
A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease
2001
Donepezil provides benefits in global function in moderate to severe Alzheimer's disease
2000